Revolution Medicines, Inc. (RVMD) Institutional Ownership & Insider Trading

687 institutions reported holding Revolution Medicines, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 161 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RVMDRevolution Medicines, Inc.Follow RVMD — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 40.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

687 institutions held 99.9% of the shares. Across filers that reported both quarters, shares held changed +8.5%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	687	214	+8.5%	231	220	139	54
Mar 26	508	196	-0.9%	154	142	120	32
Dec 25	383	201	+1.3%	128	83	94	26
Sep 25	315	194	+2.7%	103	50	86	34
Jun 25	304	191	-1.2%	104	49	84	28
Mar 25	281	191	+1.6%	89	40	80	34
Dec 24	276	193	+9.4%	119	40	53	27
Sep 24	250	169	+0.1%	83	49	60	16

Revolution Medicines, Inc. — questions

Who owns Revolution Medicines, Inc. stock?: 687 institutions reported Revolution Medicines, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (6.4%), FARALLON CAPITAL MANAGEMENT LLC (6.3%), FMR LLC (5.7%).
Are Revolution Medicines, Inc. insiders buying or selling?: 161 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Revolution Medicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.